newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 (GLOBE